Sernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 Diabetes
Clinical Study on Track to Meet its Primary and Secondary Endpoints Data Demonstrate That Metabolic Measures Improve with Cumulative Quantities of Transplanted Donor Islets Data Demonstrate Islet Engraftment in Cell Pouch and Islet Functionality, Including C-Peptide Production All Patients Reached or Maintained the ADA Recommended HbA1c of <7.0% Patient Reported Data Show an Improved Awareness of Onset of Hypoglycemia, a Reduction of Fear of Hypoglycemic Events and a Reduction in Distress Associated with Ma ...